OTX2

Across TCGA pan-cancer cohorts, OTX2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OTX2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OTX2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OTX2 expression acts as an unfavorable survival marker.

HNSC, LIHC, and BLCA are the cancer types where OTX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.102	0.712	<.001	48	view →
LIHC	OS	Median	II,III,IV	0.051	0.772	<.001	27	view →
BLCA	OS	Median	III,IV	0.526	0.655	<.001	16	view →
SKCM	OS	Median	IV	0.179	0.727	<.001	15	view →
BRCA	OS	Median	II,III,IV	0.657	0.912	.037	6	view →
ACC	OS	Median	All	0.147	0.685	.018	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OTX2–HNSC (DFS)

Open the HNSC breakdown →